Neumora Therapeutics is trading 10.26% lower at $0.42, with no direct catalyst identified for the October 21 decline.
- XBI is up 2.10% and major indexes are higher, so the decline is moving against broader trends.
- Reports of older clinical-trial setbacks surfaced, but no evidence ties them to this session’s move. Trading volume was not provided, and the cause remains unclear.